China index futures morning session close: CSI 300 (IF) main contract -0.32%; SSE 50 (IH) main contract +0.22%; CSI 500 (IC) main contract -1.52%; CSI 1000 (IM) main contract -1.14%.

At its Oct. 12, 2026 interim results briefing, Weiao Co. said it will continue to optimize its automotive operations, align the auto business with the development of its core rail‑transit operations and new business development, and make timely strategic adjustments to its auto‑parts unit to improve overall operating quality. The company said it is not currently involved in low‑altitude economy businesses.

China A-share innovative drug sector showed pockets of strength; Lamei Pharmaceutical hit the 20% limit-up, North China Pharmaceutical hit limit-up, and Mengke Pharmaceutical-U, Tainuo Maibo-U and Zhongheng Group also advanced.